Loading...
Aurobindo Pharma Ltd — Naproxen Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Naproxen · $6.3M export value · DGFT Verified
Aurobindo Pharma Ltd is the #7 Indian exporter of Naproxen with $6.3M in export value and 372 verified shipments. Aurobindo Pharma Ltd holds a 4.7% market share in Naproxen exports across 3 countries.
| Country | Value | Shipments | Share |
|---|---|---|---|
| MALTA | $5.8M | 516 | 84.7% |
| UNITED KINGDOM | $461.7K | 13 | 6.8% |
| UNITED STATES OF AMERICA | $352.4K | 8 | 5.2% |
| NETHERLANDS | $214.4K | 17 | 3.1% |
| PORTUGAL | $16.5K | 1 | 0.2% |
Aurobindo Pharma Ltd exports Naproxen to 5 countries. The largest destination is MALTA accounting for 84.7% of Aurobindo Pharma Ltd's Naproxen shipments, followed by UNITED KINGDOM (6.8%) and UNITED STATES OF AMERICA (5.2%). These destinations reflect Aurobindo Pharma Ltd's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| APL SWIFT SERVICES (MALTA) LTD., | MALTA | $2.9M | 291 |
| APL SWIFT SERVICES MALTA LIMITED | MALTA | $1.0M | 74 |
| APL SWIFT SERVICES MALTA LTD | MALTA | $620.3K | 52 |
| APL SWIFT SERVICES (MALTA) LIMITED | MALTA | $478.6K | 34 |
| MILPHARM LIMITED | UNITED KINGDOM | $376.9K | 9 |
India exported $77.8M worth of Naproxen through 3,414 shipments from 192 suppliers to 76 countries, serving 366 buyers globally. Aurobindo Pharma Ltd contributes $6.3M to this total, accounting for 4.7% of India's Naproxen exports. Aurobindo Pharma Ltd ships Naproxen to 5 countries through 19 buyers.
Aurobindo Pharma Ltd's average Naproxen shipment value is $16.9K per consignment, based on 372 shipments totaling $6.3M. The largest destination is MALTA (84.7% of Aurobindo Pharma Ltd's Naproxen exports).
Aurobindo Pharma Ltd ranks #7 among 192 Indian Naproxen exporters with a 4.7% market share. The top 3 exporters are GLENMARK PHARMACEUTICALS LIMITED ($14.1M), UNICHEM LABORATORIES LIMITED ($13.8M), GRANULES INDIA LIMITED ($8.5M). Aurobindo Pharma Ltd processed 372 shipments to 3 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| NAPROXEN 500MG TABLETSNaproxen Aurobindo 500 mg tabletten30'S | $245.1K | 8 |
| NAPROXEN 500MG TABLETS(APO-NAPRO, 500 MG, TABLETKI)30'S | $229.2K | 19 |
| NAPROXEN 500MG TABLETS(Naproxen Aurobind | $219.2K | 11 |
| NAPROXEN 250MG TABLETS(Apo-Napro, 250 mg | $214.4K | 12 |
| NAPROXEN 500MG TABLETSApo-Napro 500 mg tabletki30'S | $213.2K | 6 |
| NAPROXEN 500MG TABLETS, (Naproxen Aurobi | $192.2K | 6 |
| NAPROXEN 500MG TABLETS(Apo-Napro, 500 mg | $186.9K | 8 |
| NAPROXEN 500MG TABLETS (NAPROXEN TABLETSBP 500 MG) 2X14'S | $179.0K | 4 |
| NAPROXEN 500MG TABLETS(Naproxeno Generis |
What Aurobindo Pharma Ltd must comply with to export Naproxen to its top destination countries
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | UNICHEM LABORATORIES LIMITED | $13.8M | 276 | 1 | $50.0K |
| 5 | GRANULES INDIA LIMITED | $8.5M | 191 | 2 | $44.3K |
| 7 | AUROBINDO PHARMA LTD ★ | $6.3M | 372 | 3 | $16.9K |
| 4 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $6.0M | 119 | 1 | $50.0K |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 429 | 12.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 245 | 7.2% |
| SAHAR AIR | 236 | 6.9% |
| DELHI AIR CARGO ACC (INDEL4) | 211 | 6.2% |
| JNPT/ NHAVA SHEVA SEA | 156 | 4.6% |
| HYDERABAD ICD | 145 | 4.2% |
| VIZAG SEA | 140 | 4.1% |
| BANGALORE AIR | 128 | 3.7% |
Latest developments and market context
Detailed market intelligence for Naproxen — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Aurobindo Pharma Ltd's Naproxen exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
| MALTA |
| $335.6K |
| 18 |
| XXL SXXFT XXRVIXXS (XXLTAXXLIMXXED | MALTA | $279.6K | 11 |
| XXROBXXDO XXARMXXUSAXXNC | UNITED STATES OF AMERICA | $252.4K | 6 |
| APL SWIFT SERVICES (MALTA) LIMITED, | MALTA | $130.4K | 32 |
| XXROHXXLTHXXLC | UNITED STATES OF AMERICA | $100.0K | 2 |
Aurobindo Pharma Ltd supplies Naproxen to 19 buyers globally. The largest buyer is APL SWIFT SERVICES (MALTA) LTD., (MALTA), followed by APL SWIFT SERVICES MALTA LIMITED (MALTA) and APL SWIFT SERVICES MALTA LTD (MALTA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $168.9K |
| 11 |
| NAPROXEN 500MG TABLETS(APO-NAPRO 500MG T | $163.0K | 7 |
Aurobindo Pharma Ltd exports 271 distinct Naproxen formulations including tablets, capsules, syrups, and combination drugs. The top formulation is NAPROXEN 500MG TABLETSNaproxen Aurobindo 500 mg tabletten30' with 8 shipments worth $245.1K.
| 8 |
| MARKSANS PHARMA LIMITED |
| $5.1M |
| 149 |
| 2 |
| $34.3K |
Aurobindo Pharma Ltd ranks #7 among 192 Indian Naproxen exporters. Average shipment value of $16.9K compared to the market average of $405.2K. The closest competitors by value are UNICHEM LABORATORIES LIMITED and GRANULES INDIA LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 76+ countries, 366+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Aurobindo Pharma Ltd.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Naproxen. For current shipment-level data, contact TransData Nexus.